ChrysCapital.
India's largest domestic PE franchise: a record $2.2bn Fund X (Nov 2025) with the first-ever domestic LP sleeve, $7.8bn realised across 80 exits at ~3.0x, the $700M NSE continuation vehicle, and the NSE mega-IPO as the pending crown jewel.
GW GP Score
ChrysCapital is 27 years of Indian PE compounding: nine funds fully or largely harvested ($7.8bn realised, ~3.0x aggregate), the country's continuation-vehicle pioneer (NSE, $700M, oversubscribed in two months), and now the record-setter: Fund X's $2.2bn including ~$300M from ~50 domestic institutions, a first. The 2025-26 deployment shows the new shape: control QSR (Theobroma at ₹2,410 Cr), MNC take-privates (Novartis India consortium), EMS manufacturing (Nash). Dream11's RMG impairment is the venture-era scar; the NSE stake riding into India's largest-ever IPO is the it-could-all-work moment.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
NSE IPO (~₹30,000 Cr): timing and ChrysCapital's OFS size.
Lenskart IPO-seller conflict across sources.
NSE concentration: the CV's resolution depends on one mega-IPO's timing and pricing.
Computed from current dossier sources; analyst override pending.
The deepest realisation record and the biggest fund in Indian PE, run by a post-founder institution that keeps re-inventing its liquidity toolkit. Positive, with NSE as the swing event.
NSE + Theobroma + healthcare platform; Dream11 impaired
$7.8bn/3.0x long-run + GeBBS 17x EBITDA + CV innovation
Industrials/healthcare focus is sturdy, not visionary; no AI thesis
Record fund, record speed, new LP geographies + domestic sleeve
Post-founder institution 13 years on; orderly MP elevation
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
NSE liquidity clears with credible OFS/block-sale evidence.
Any RMG-ban litigation or legislative movement; DreamStreet traction as the stated pivot.
NSE IPO (~₹30,000 Cr): timing and ChrysCapital's OFS size.
The domestic sleeve is the story: Indian institutions can finally buy the flagship. Diligence the per-fund IRRs the firm itself publishes, and ask how Fund X avoids paying 2026 prices for 2019-style assets.
NSE concentration: the CV's resolution depends on one mega-IPO's timing and pricing.
NSE IPO (~₹30,000 Cr): timing and ChrysCapital's OFS size.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 1 pressure catalyst(s); top driver: Dream Sports shuts its fintech arm as the RMG ban keeps biting.
Dream Money, the mutual-funds/digital-gold/lending arm launched Aug 2025 to offset the real-money-gaming ban's revenue hit, is closing by 2026-07-30; the company frames it as refocusing on its DreamStreet stock-broking unit.
Score pressureConfirms the Dream11 impairment thesis is still deepening rather than recovering across every book holding the position.
Any RMG-ban litigation or legislative movement; DreamStreet traction as the stated pivot.
The funds
~$8.5bn raised · $5.5bn deployed · $7.8bn realised across 4 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| Fund X | 2025Recovery / IPO window | $2.2bn | Buyout + growth | First-to-final in ~6 months; ~85% international + first domestic sleeve (~$300M, ~50 institutions) |
| NSE Continuation Vehicle | 2024Recovery / IPO window | $700M | Single-asset CV | HarbourVest, Pantheon, LGT; India's largest CV: NSE IPO is the resolution |
| Fund IX | 2022Correction onset | $1.35bn (C) | Buyout + growth | Xoriant, ProHance era |
| Clarus (public markets) | 2023Trough window | ~$200M open-ended | Listed equities | Cat-III AIF: the crossover arm |
Closest booksChiratae Ventures (2 shared) · Premji Invest (1 shared) · Tiger Global (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle closed inside the current exit/repricing window.
Next liquidityNSE · Lenskart · FirstCry · Hero Fincorp · Corona Remedies
3 visible exit events since Jul 2024.
Latest vehicle closed inside the current exit/repricing window.
8 up / 2 flat / 1 down tracked signals.
No senior departure flagged in key people.
8 up / 2 flat / 1 down
3 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangDream11 (Dream Sports): names with negative 12-month mark or momentum signals in the reconstructed book.
Exit-led repricing; entry discipline decisive
Exit-led repricing; entry discipline decisive
Repricing began mid-deployment
Best entry conditions of the cycle
DRHP filed for ~₹30,000 Cr IPO: India's largest ever; ChrysCapital among sellers
IPO-seller status conflicting across sources (C)
Not in IPO OFS lists; holding unverified (E)
IPO pending (E)
Dec 2025 IPO; trimmed 27% → 21% (6.7x or 23% IRR: sources conflict)
At least one cited source is dated 2026.
5 visible events tracked.
11 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 4 · 0
Peer median 4 · +1
Peer median 91 · -1
Peer median 66 · -1
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Team data evidence remains low-confidence despite a scored dossier.
Current · At least one cited source is dated 2026.
Upgrade the weak fields with dated facts before the next score action: Team data.
Prioritise filings and firm disclosures; mark estimates as GW E until then.
Lenskart IPO-seller conflict across sources.
NSE: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Team data.
6 total sources · 17% primary
At least one cited source is dated 2026.
Business Standard: Dream Money shuts after RMG ban ends Dream11 fintech foray (Jul 2026)
Upgrade Team data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
110 companies backed over 27 years. 11 tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| NSE | Fintech | 2016 | 5% → CV (2024) | Private | ▲ | DRHP filed for ~₹30,000 Cr IPO: India's largest ever; ChrysCapital among sellers |
| Theobroma | Consumer & Commerce | 2025 | 90% for ₹2,410 Cr | Private | ▲ | QSR platform anchor; ICICI Venture's full exit |
| Lenskart | Consumer & Commerce | 2023 | ~$100M (ADIA-led round) | Public | ▲ | IPO-seller status conflicting across sources (C) |
| Dream11 (Dream Sports) | Consumer & Commerce | 2020 | $225M co-led (w/ Tiger, TPG) | Unicorn | ▼ | Last marked $8bn (2021); RMG banned Aug 2025: impaired |
| FirstCry | Consumer & Commerce | 2021 | Part of $315M round | Public | → | Not in IPO OFS lists; holding unverified (E) |
| Xoriant | SaaS & Dev Tools | 2023 | Buyout | Private | ▲ | Ninth business-services buyout |
| Centre for Sight | Healthcare | 2024 | Up to ₹830 Cr | Private | ▲ | Eye-care chain; bought Mahindra's stake |
| La Renon Healthcare | Healthcare | 2024 | ~$70M secondary at ₹6,500 Cr | Private | ▲ | — |
| Novartis India | Healthcare | 2026 | Consortium take-private (10.32% via Fund X) | Public | ▲ | ₹1,446 Cr for Novartis AG's 70.68% + open offer: the MNC carve-out play |
| Hero Fincorp | Fintech | 2016 | Growth | Private | → | IPO pending (E) |
| Corona Remedies | Healthcare | 2021 | Secondary | Public | ▲ | Dec 2025 IPO; trimmed 27% → 21% (6.7x or 23% IRR: sources conflict) |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
Fund X's stated hunt is industrials and healthcare, and the first three prints deliver exactly that: EMS manufacturing, a pharma MNC take-private, plus the QSR control anchor. The domestic-LP sleeve matters strategically: Indian institutions now have direct exposure to Indian PE's flagship.
EMS/metal stamping: the industrials thesis
Realisation · are LPs getting paid?
The long-run numbers are the argument: $7.8bn realised, 80 exits, ~3.0x, with fund-level claims (Fund III at 89% IRR/4.0x) on the firm's own site. The 2024-26 window added a ~17x-EBITDA strategic sale, clean pharma block exits and the CV, with NSE's mega-IPO as the deferred jackpot.
₹655 Cr all-OFS listing; trimmed to 21%; 6.7x / 23% IRR (conflicting retail-adjacent sources).
Sold to EQT at ~$850M EV, ~17x EBITDA: the 2018 control entry's clean win.
Full exit: 7.27% for ₹1,187 Cr.
OFS + Dec 2024 block (part of ₹583 Cr): substantially exited.
$700M continuation vehicle: LP liquidity while retaining the asset for the IPO.
80 exits across 27 years: the deepest realisation base in Indian PE
30+ new global LPs + first domestic sleeve
Resolution rides India's largest-ever IPO
The venture-crossover era's cost, banned by statute
More performance disclosure than any Indian PE peer (aggregate ROI, per-fund IRRs on its own site, albeit self-reported). GW read: the record fundraise validates the record; the watch is whether Fund X's size forces style drift from the mid-market wheelhouse. E.
What they're doing
Fund X hunts industrials and healthcare: control where possible (Theobroma, Novartis consortium, Nash).
Liquidity toolkit breadth: CVs (NSE), public-markets AIF (Clarus), block discipline, strategic sales.
Domestic-LP sleeve as a strategic moat: Indian institutional capital inside the flagship.
MNC carve-outs as a repeatable play (Novartis India; 120-day rename clock).
What can break
NSE concentration: the CV's resolution depends on one mega-IPO's timing and pricing.
Dream11's impairment shows the crossover book's statute risk, and it was ChrysCapital's biggest venture-style cheque.
$2.2bn must deploy into a mid-market that record dry powder is repricing.
NSE IPO (~₹30,000 Cr): timing and ChrysCapital's OFS size.
Lenskart IPO-seller conflict across sources.
Fund IX size discrepancy ($1.25bn site vs $1.35-1.4bn press).
Dream11 mark resolution post-RMG ban.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
The domestic sleeve is the story: Indian institutions can finally buy the flagship. Diligence the per-fund IRRs the firm itself publishes, and ask how Fund X avoids paying 2026 prices for 2019-style assets.
ChrysCapital's CV playbook (NSE) and take-private consortium model (Novartis) are templates for your own stuck positions and MNC conversations. Its $2.2bn also just repriced every mid-market auction you're in.
The NSE IPO, with ChrysCapital selling: will be the largest liquidity event in Indian capital-markets history; everything on our pipeline page trades in its shadow.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.